Shilpa Medicare Limited’s joint venture, Oncosol, in partnership with Shorla Oncology, has announced the USFDA approval of IMKELDI, an advanced oral liquid formulation of imatinib. This groundbreaking drug targets various forms of leukemia and gastrointestinal tumors (GIST). The approval highlights significant strides in providing a patient-friendly alternative for treating chronic myeloid leukemia (CML), acute lymphoblastic leukemia, myelodysplastic syndrome (MDS/MPD), and GIST.
Key highlights:
- IMKELDI is the first of its kind, focusing on dosing precision and ease of administration for cancer patients.
- The drug aims to address the unmet need for patient adherence by offering a liquid formulation, which simplifies treatment regimens.
Projected U.S. Statistics for 2024:
- 9,280 individuals diagnosed with CML.
- Over 10,000 cases of MDS/MPD.
- Up to 6,000 individuals with GIST.
Shilpa Medicare, headquartered in Raichur, Karnataka, continues to excel in oncology drug development. By introducing innovative treatments like IMKELDI, the company underscores its commitment to improving patient care and access to life-saving therapies globally.
